Summary
PRA Health Sciences Late Phase Services is participating in a global real world safety study program, mandated by various regulatory bodies, to confirm risk/benefit profile for a novel oral anticoagulant to assess the drug’s bleeding risk. Our ability to provide global operational oversight and efficiencies, ensure consistent communication with sites, and keep our patients engaged resulted in PRA becoming the client’s CRO of choice.
Register to download
Challenging Study Timeline Goals Achieved in Global Post-Authorization Safety Study (PASS)
You may also be interested in:
Webcast
THE INSIGHT SERIES: Can you use the same outsourcing methodologies for post-marketing studies as pre-approval research? - Part 4
As the number of preferred provider relationships grow and become more sophisticated, budget grids and assumptions must align with the needs of…
White Paper
Synthetic Control Arms: Considerations Around Definition, Drivers, and Design
Those that work in the biopharmaceutical or device industry are likely familiar with the term synthetic controls. But what exactly are synthetic…
Case Study
Meeting Enrollment Goals Breast Cancer
An open-label, randomized, multi-center study to evaluate the use of Study Drug in the prevention of cancer treatment-related bone loss in…